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Abstract
Background: HPV DNA is found in almost 80% of VIN/VaIN. Current management is inadequate, with high recurrence
rates. Our objective was to review the literature regarding the role of HPV vaccine in secondary prevention and treatment
of VIN/VaIN.
Methods: Database searches included Ovid Medline, Embase, Web of Science, The Cochrane Library and Clinicaltrials.gov.
Search terms included HPV vaccine AND therapeutic vaccine* AND VIN OR VAIN, published in English with no defined
date limit. Searches were carried out with a UCL librarian in March 2018. We included any type of study design using any
form of HPV vaccine in the treatment of women with a histologically confirmed diagnosis of VIN/VaIN. We excluded
studies of other lower genital tract disease, vulval/vaginal carcinoma and prophylactic use of vaccines. The outcome
measures were lesion response to vaccination, symptom improvement, immune response and HPV clearance.
Results: We identified 93 articles, 7 studies met our inclusion criteria; these were uncontrolled case series. There were
no RCTs or systematic reviews identified. Reduction in lesion size was reported by all 7 studies, symptom relief by 5,
HPV clearance by 6, histological regression by 5, and immune response by 6.
Conclusions: This review finds the evidence relating to the use of HPV vaccine in the treatment of women with VIN/
VaIN is of very low quality and insufficient to guide practice. Further longitudinal studies are needed to assess its use in
prevention of progression to cancer.
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Background
Vulval/Vaginal Intraepithelial Neoplasia (VIN/VaIN) can
precede the development of invasive cancer by a variable
period. Usual-type VIN (uVIN) is commonly associated
with carcinogenic subtypes of human papillomavirus (most
commonly HPV 16) [1]. The HPV attribution for different
anogenital lesions varies between studies, however, is found
in approximately 76–87% of VIN, 30–40% of vulvar cancer
[1], 96% of VaIN and 63–74% of vaginal cancer [2, 3].
The incidence of VIN is thought to be around 1–2/
100,000 [4]. Although spontaneous regression has been
reported (approx. 1.2%), VIN is considered a premalig-
nant condition (as is VaIN), with a suggested progression
rate to cancer of 3–16% [5]. Although primarily seen in
older women (over 70 years old), 15% are diagnosed in
women under the age of 50. Although presentation of
VIN may be asymptomatic, symptoms often include
pruritis, burning, and pain which can be distressing [6].
In addition, lesions may be multifocal affecting large
areas of the vulva, pigmented or white or present as
areas of erythema. Lesions may also be flat, raised or ul-
cerated [5].
Vaginal Intraepithelial neoplasia is an uncommon (in-
cidence around 0.1/100,000 women in the US) usually
asymptomatic disease [7], often associated with other
intraepithelial neoplasias. Progression to invasive vaginal
cancer has been reported as approximately 2% [8].
The current treatments for VaIN are either surgical
(excision or CO2 ablation) or medical (Imiquimod, 5FU
or vaginal oestrogens) [9]. Most treatment regimens for
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VIN also consist of ablation or excision, medical therapy
with Imiquimod has been shown to be effective [10] and
is commonly used by dermatologists and genitourinary
medicine (GUM) specialists. Its use can be limited by in-
tolerable side effects such as erythema and vulval pain.
Recurrence rates after treatment, regardless of modality
are as high as 30–50%, implying that current treatment
options are inadequate and not effective in the long term
[11]. A review of practice at our unit showed poor response
rate to all treatment modalities with rate of progression to
invasive disease at 16%. Almost 15% of patients attend for
10 years or more, undergoing multiple biopsies and/or
surgical treatments, in addition to being on long term Imi-
quimod treatment. These women participate in multiple
hospital visits which is a burden to them and increases
healthcare services costs. These findings from our own
practice prompted this systematic review.
Women with natural antibodies to HPV have less fre-
quent recurrence of VIN than those who are antibody
negative (22.9% vs 52%) [12]. Three vaccines are avail-
able for the primary prevention of HPV infection. A
bivalent vaccine (Cervarix® [GSK]) targets high risk HPV
types 16 and 18, whilst a quadrivalent vaccine (Gardasil®)
targets the same HR HPV types (16 and 18) and two
HPV types that commonly cause genital warts (6, 11). A
newer recombinant 9-valent vaccine prepared from the
purified virus-like particles (VLP) of the major capsid
(L1) protein of the 9 HPV subtypes - 6, 11, 16, 18, 31,
33, 45, 52, 58, is now available (Gardasil® 9 [MSD UK]).
These are widely used for the prevention of premalig-
nant genital lesions, and premalignant anal lesions, in
females and males. These appear to be most effective at
preventing CIN in women who are known to be HRHPV
negative, but there is moderate to high quality evidence
that they reduce high grade CIN for women whose HPV
status is not known [13–15]. This may be because
prophylactic vaccination has been shown to augment the
response to HPV in women who were previously sero-
positive [16]. This is consistent with studies that indicate
that vaccination may have a therapeutic effect in other
HPV-associated conditions such as recurrent respiratory
papillomatosis (RRP), a benign neoplasm of the larynx
among children, caused by HPV 6 and 11 [17].
Prophylactic vaccines act by inducing neutralising
antibodies to the viral L1 capsid proteins. It is thought
that treatment of already established HPV infection re-
quires activation of T-cells capable of killing virus infected
cells, rather than producing antibodies against the
virus itself, so therapeutic vaccines (in development),
target viral genome E6 and E7 oncoproteins (necessary
for initiation and maintenance of transformation to
cancer) [18].
Different types of therapeutic vaccines have been tested
in other HPV driven diseases. These include;
 Protein-based vaccines, which can be long or short
peptide chains, and comprise TA-CIN (Tissue Antigen
Cervical Intraepithelial Neoplasia) a fusion protein of
HPV 16 L2, E6 and E7 [18, 19];
 DNA based vaccines that induce cytotoxic lymphocytes,
T helper cells, and increase B cell immunity;
 A vaccine containing a mixture of two plasmids
encoding HPV 16/18 E6 and E7 antigens;
 TA-HPV (therapeutic antigen HPV) a vaccinia
vector-based vaccine expressing modified forms of
HPV 16 and 18 E6 and E7 proteins and
 Cell-based vaccines such as dendritic cells and
tumour infiltrating T-cells [18].
The currently licensed HPV vaccines have an estab-
lished role in the primary prevention of HPV infection
generally in younger populations. The role of the HPV
vaccine in secondary prevention and treatment has not
yet been fully established. Women with VIN may have
symptoms which are recurrent and difficult to treat. Clini-
cians who treat these patients (dermatologists, GUM spe-
cialists and gynaecologists) look for ways to improve the
effectiveness of current treatment.
We performed a review of the literature regarding the
role of any HPV vaccination for secondary prevention, in
the treatment of women with HPV-related VIN and VaIN.
Methods
We conducted a systematic search of the literature with
the strategy to review best available evidence. We searched
for systematic reviews, and randomized controlled trials.
If these were not available, we would include controlled
non-random studies, and uncontrolled studies. We looked
into the use of any form of HPV vaccine in the treatment
of women with a histologically confirmed diagnosis of
HPV related VIN and/or VaIN, versus control/standard
treatment. These vaccines included the commercially
available licensed vaccines prepared from the VLPs of the
L1 protein of common HPV types, or the experimental
vaccines against the HPV oncoproteins E6/E7. Our search
also included vaccines as adjuvant to usual care. We ex-
cluded studies of other lower genital tract disease (pre-in-
vasive or invasive), vulval/vaginal carcinoma and those
studies concerning prophylactic use of vaccines.
We excluded studies whose participants were pregnant,
immunocompromised, or had a history of allergy to vac-
cine products. In the included studies, patients with VIN
or VaIN were given any form of HPV vaccination.
The outcome measures we wished to evaluate were le-
sion response to vaccination, symptom improvement,
immune response, and HPV clearance. A Core Outcome
Set protocol was not used as this is not currently avail-
able but is in development for vulva.
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Database searches included Ovid Medline, Embase, Web
of Science, The Cochrane Library and Clinicaltrials.gov.
Search terms included HPV vaccine OR Human Papilloma
Virus vaccine OR Papilloma virus vaccines OR HPV Vac-
cin* AND therapeutic vaccine* AND VIN OR VAIN OR
Vulval intraepithelial neoplasia OR Vaginal intraepithelial
neoplasia, published in English with no defined date limit.
Database searches were carried out with the aid of a UCL
librarian in March 2018. Additional papers were identified
via the reference lists of included studies (Additional file 1).
Results
Our search strategy is detailed in the Prisma flow diagram
in Additional file 2: Figure S1. Two independent reviewers
identified 93 articles after excluding studies with titles unre-
lated to the subject matter. A further 86 articles were ex-
cluded at this stage: 55 were review articles i.e. not primary
research or not addressing the review question. Seventeen
studies were excluded as they reported on experimental
HPV vaccine development - identifying the right dose for
effect or analyzing the types of immune response to HPV
vaccination. Four studies were concerned with HPV vaccine
as prevention not as treatment and three studies were
concerned with effect of experimental HPV vaccine in
non-human subjects. In a search of clinicaltrials.org we
found 4 potential studies – two were active trials but not
yet recruiting, with results expected in late 2018 – one in-
volved CIN only and the other, a study from China which
had completed, but no results had been reported at the
time of writing. Two studies were concerned with other
forms of anogenital pre-cancer and 1 study was concerned
with trial of Imiquimod only.
There were no RCTs, systematic reviews or controlled
studies identified. Seven studies that included 129 women,
met our inclusion criteria, the included studies were all
uncontrolled case series published between 2000 and 2017
(Table 1).
Study participants
Of the 129 participants 126 had VIN and 3 had VAIN
[19–25]. Duration of disease (VIN/VAIN) ranged from
2months to 17 years, with approximately 60% of patients
having had previous treatment(s). In two of the studies
the women had a mean age of 29 whilst the other stud-
ies’ participants were over the age of 40 years. The stud-
ies showed heterogeneity in the number of patients
included (12 to 29) and disease duration prior to vaccin-
ation (2 months to 17 years), whilst the follow up was
equally short (1–12months) in all.
Intervention
None of the studies used the commercially available vac-
cines. All of the studies used experimental vaccines of ei-
ther TA-HPV (therapeutic antigen HPV) a vaccinia-based
vector vaccine, or TA-CIN (Tissue Antigen Cervical Intrae-
pithelial Neoplasia), a fusion protein vaccine comprising
HPV16 viral proteins L2, E6 and E7 – the latter 2 respon-
sible for inactivation of the tumour suppressor proteins p53
and pRb respectively, leading to hyper-proliferation of host
cells and overexpression of p16 and p14 [5], which can lead
to cancer.
Outcomes
Change in lesion size pre and post HPV vaccination was
an outcome reported by all 7 studies. Symptom relief
was reported by 5 studies, HPV clearance by 6 studies,
histological regression by 5 studies, and immune re-
sponse by 6 of the 7 studies. Follow-up was short - most
commonly from 1month to 1 year.
Lesion response to experimental HPV vaccination
Regression of the lesion was assessed by measuring le-
sion size before and after vaccination, commonly in two
dimensions and taking the average of both sizes. Most of
the studies categorized these into partial response (if
more than a 50% reduction in size), no response (if less
than 50% reduction) or complete response if no lesion
was visible following vaccination. In these studies, lesion
regression varied from no response up to an overall par-
tial and complete response of 83%.
Symptom relief
Clinical improvement in symptoms was measured by
either direct questioning at each visit or by asking par-
ticipants to keep a symptom diary. Although no formal
validated tool was used, commonly, symptoms were
subjectively graded into none/mild/moderate/severe,
depending on how it affected patient’s daily lives. The
effects on symptom relief varied from no overall change
in symptoms to 68.4% of women becoming symptom
free after the follow up period.
Immune response to experimental HPV vaccination
Immune response to vaccination ranged from 30 to 94%.
Various different markers were used to determine im-
mune responses (T-cell responses vs lymphoproliferative
vs cytokine). The types of experimental vaccines, sched-
ules and in some cases delivery method, also differed
and this may contribute to the heterogeneity seen be-
tween study findings.
HPV clearance
HPV clearance is defined as testing HPV negative post
vaccination having previously tested positive. The rate of
HPV clearance varied between 8 and 74%. Histological
regression is defined as the index VIN/VaIN lesion being
downgraded from a high grade to a low-grade lesion.
The rate of this occurring varied from 0 up to 63%. HPV
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status and histological regression did not seem to correlate
with regression of the lesion nor the patient’s symptoms.
There was a wide variation in results in relation to the
above outcomes, which may reflect the differences in pa-
tients and the types of vaccines and schedules used.
Discussion
This study is the first systematic review of the use of any
HPV vaccination in the treatment of HPV related vulval
and vaginal disorders. This review has highlighted that
no high-quality studies using commercially available vac-
cines have addressed this research question - available
vaccines are designed for prevention. Studies that have
been carried out are small, case series without control
groups, rather than randomized controlled trials. They
have used experimental therapeutic vaccines rather than
the available vaccines. The study designs are of low meth-
odological quality and a high risk of bias. Systematic re-
views of randomized control trials indicate that available
HPV vaccines are safe and effective for prevention. Effect-
iveness seems to decrease with age and exposure to HPV.
The role of these vaccines as adjuvant to treatment has
not been studied. The efficacy and safety of the experi-
mental vaccines is yet to be established and it is likely to
be a number of years before therapeutic vaccines become
available for clinical use. Overall the evidence to answer
the clinical questions of the role of HPV vaccination in
the treatment of VIN/VAIN is of very low-quality.
Clinical responses to experimental HPV vaccine
When comparing other systematic reviews and studies
evaluating treatment outcomes for vulval disease, reporting
centers primarily on response to treatment, with response
being described as resolution, persistence or progression.
This could be assessed clinically as a reduction in size of
the lesion, symptoms response as reported by the patients,
histological resolution (this assessment is invasive because
it requires repeat biopsies), HPV clearance or persistence.
A number of patients experienced relief of their symp-
toms post vaccination. A large number also experienced
a reduction in the size of their lesions - it is unclear
whether this correlates with symptom relief. Current
treatments for VIN may be effective in the short term but
with significant side effects and a high risk of recurrence.
Of the studies which we identified, one reported no re-
sponse in any of the initial outcome measures after 3
months [25]. In this study the novel technique of intra-
dermal tattooing was used. This technique has been
evaluated in animal models and the efficacy compared to
traditional intramuscular vaccination has not been estab-
lished in humans. The method of vaccination may have
contributed to these negative results.
Strengths and limitations
Our review examines the role of HPV vaccination as an
adjuvant to treatment for women who have HPV related
VIN/VaIN. Whilst Miltz et al have examined the role of
vaccination in anogenital pre-cancer [26], our review dif-
fers in that it focuses on vulval and vaginal diseases ra-
ther than cervical/CIN. We were interested in exploring
interventions that could be used alongside existing treat-
ments for VaIN and VIN to improve effectiveness and/
or reduce recurrence and need for further treatments.
We used a systematic approach to search library data-
bases. None of the studies directly compared a control
group with HPV vaccination, all studies found were un-
controlled case series, with short follow up for what is a
chronic, long term disease. We were therefore limited by
the level of evidence with which to answer the question.
Conclusion
Women with VIN/VaIN are living with chronic condi-
tions, requiring prolonged and often repeated treatments
which can have intolerable side effects, and yet high re-
lapse rates. More effective treatments are needed that will
reduce symptoms, reduce progression and reduce the rate
of relapse. Having been introduced almost a decade ago as
part of the childhood vaccination program, we should
begin to see a reduction in the incidence of VIN/VAIN
and other anogenital pre-cancers. In the meantime, for pa-
tients who have not been vaccinated, newer treatments
with fewer side effects and morbidity are warranted. The
evidence for the use of HPV vaccination in VIN/VaIN is
of low quality and insufficient to guide practice. All of the
vaccines used in these non-randomized studies were ex-
perimental and we did not find any research evaluating
the use of commercially available vaccine as an adjuvant
to usual treatment of VAIN/VIN. We aim to deliver such
a study following on from this review. More studies are
needed to investigate clinically important patient out-
comes (symptoms, non-progression and recurrence rates)
with the use of HPV vaccine in a therapeutic setting. It
would be prudent to also investigate its use in secondary
prevention of cancer, which would need to be assessed
through further longitudinal studies.
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